Back to News
Latest MHRA Drug Safety Update - January 2018
Posted on 16 Jan 2018
The latest MHRA Drug Safety Update, January 2018
This month article features are:
- important new advice about the multiple sclerosis medicine daclizumab (daclizumab beta; Zinbryta▼) following a European review of the risk of severe liver injury (page 2). Note carefully and act on the new restricted indication, contraindications and warnings, and monitoring requirements. Review any patient receiving daclizumab to check that this treatment remains appropriate and ensure they understand the risks before continuing or initiating daclizumab.
- advice on a very rare risk of severe cutaneous adverse reactions associated with recombinant human erythropoietins (page 4). Discontinue erythropoietins permanently if a patient develops a severe cutaneous adverse reaction such as Stevens-Johnson syndrome or toxic epidermal necrolysis.
- remind you to be vigilant for drug names that sound-like or look-like others in light of recent cases of medication error relating to drug-name confusion (page 6).
- note the prescribing and dispensing recommendations related to minimising risk of medication error and accidental overdose with co-dydramol following the launch of new products containing 20 mg and 30 mg of dihydrocodeine (page 7).
- we continue our campaign to support reporting of suspected adverse drug reactions to the Yellow Card Scheme with a reminder to ask patients about any herbal medicines they are taking and to report any suspected side effects (page 8).